#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Triple-negative breast cancer ( TNBC ) is a heterogeneous disease , characterized by aggressive clinical behavior , poor prognosis , a significantly increased risk of relapse , and shorter survival rates than patients affected by other molecular subtypes of breast cancer .
2-1	16-31	Triple-negative	abstract[2]	new[2]	appos	2-5[0_2]
2-2	32-38	breast	abstract[2]	new[2]	_	_
2-3	39-45	cancer	abstract[2]	new[2]	_	_
2-4	46-47	(	_	_	_	_
2-5	48-52	TNBC	abstract	giv	coref	2-8[4_0]
2-6	53-54	)	_	_	_	_
2-7	55-57	is	_	_	_	_
2-8	58-59	a	abstract[4]	giv[4]	coref	2-40[13_4]
2-9	60-73	heterogeneous	abstract[4]	giv[4]	_	_
2-10	74-81	disease	abstract[4]	giv[4]	_	_
2-11	82-83	,	abstract[4]	giv[4]	_	_
2-12	84-97	characterized	abstract[4]	giv[4]	_	_
2-13	98-100	by	abstract[4]	giv[4]	_	_
2-14	101-111	aggressive	abstract[4]|event[5]	giv[4]|new[5]	_	_
2-15	112-120	clinical	abstract[4]|event[5]	giv[4]|new[5]	_	_
2-16	121-129	behavior	abstract[4]|event[5]	giv[4]|new[5]	_	_
2-17	130-131	,	abstract[4]	giv[4]	_	_
2-18	132-136	poor	abstract[4]|abstract[6]	giv[4]|new[6]	_	_
2-19	137-146	prognosis	abstract[4]|abstract[6]	giv[4]|new[6]	_	_
2-20	147-148	,	abstract[4]	giv[4]	_	_
2-21	149-150	a	abstract[4]|abstract[7]	giv[4]|new[7]	coref	13-15[89_7]
2-22	151-164	significantly	abstract[4]|abstract[7]	giv[4]|new[7]	_	_
2-23	165-174	increased	abstract[4]|abstract[7]	giv[4]|new[7]	_	_
2-24	175-179	risk	abstract[4]|abstract[7]	giv[4]|new[7]	_	_
2-25	180-182	of	abstract[4]|abstract[7]	giv[4]|new[7]	_	_
2-26	183-190	relapse	abstract[4]|abstract[7]|event	giv[4]|new[7]|new	_	_
2-27	191-192	,	abstract[4]	giv[4]	_	_
2-28	193-196	and	abstract[4]	giv[4]	_	_
2-29	197-204	shorter	abstract[4]|abstract[10]	giv[4]|new[10]	_	_
2-30	205-213	survival	abstract[4]|event|abstract[10]	giv[4]|new|new[10]	_	_
2-31	214-219	rates	abstract[4]|abstract[10]	giv[4]|new[10]	_	_
2-32	220-224	than	abstract[4]|abstract[10]	giv[4]|new[10]	_	_
2-33	225-233	patients	abstract[4]|abstract[10]|person[11]	giv[4]|new[10]|new[11]	coref	10-1[59_11]
2-34	234-242	affected	abstract[4]|abstract[10]|person[11]	giv[4]|new[10]|new[11]	_	_
2-35	243-245	by	abstract[4]|abstract[10]|person[11]	giv[4]|new[10]|new[11]	_	_
2-36	246-251	other	abstract[4]|abstract[10]|person[11]|abstract[12]	giv[4]|new[10]|new[11]|new[12]	_	_
2-37	252-261	molecular	abstract[4]|abstract[10]|person[11]|abstract[12]	giv[4]|new[10]|new[11]|new[12]	_	_
2-38	262-270	subtypes	abstract[4]|abstract[10]|person[11]|abstract[12]	giv[4]|new[10]|new[11]|new[12]	_	_
2-39	271-273	of	abstract[4]|abstract[10]|person[11]|abstract[12]	giv[4]|new[10]|new[11]|new[12]	_	_
2-40	274-280	breast	abstract[4]|abstract[10]|person[11]|abstract[12]|abstract[13]	giv[4]|new[10]|new[11]|new[12]|giv[13]	coref	3-1[0_13]
2-41	281-287	cancer	abstract[4]|abstract[10]|person[11]|abstract[12]|abstract[13]	giv[4]|new[10]|new[11]|new[12]|giv[13]	_	_
2-42	288-289	.	_	_	_	_

#Text=TNBC is clinically defined as tumors that lack expression of the estrogen receptor ( ER ) , progesterone receptor ( PR ) , and HER2 amplification .
3-1	290-294	TNBC	abstract	giv	coref	6-17[38_0]
3-2	295-297	is	_	_	_	_
3-3	298-308	clinically	_	_	_	_
3-4	309-316	defined	_	_	_	_
3-5	317-319	as	_	_	_	_
3-6	320-326	tumors	object[15]	new[15]	_	_
3-7	327-331	that	object[15]	new[15]	_	_
3-8	332-336	lack	object[15]	new[15]	_	_
3-9	337-347	expression	object[15]|abstract[16]	new[15]|new[16]	coref	16-7[112_16]
3-10	348-350	of	object[15]|abstract[16]	new[15]|new[16]	_	_
3-11	351-354	the	object[15]|abstract[16]|abstract[18]	new[15]|new[16]|new[18]	appos	3-15[0_18]
3-12	355-363	estrogen	object[15]|abstract[16]|substance|abstract[18]	new[15]|new[16]|new|new[18]	_	_
3-13	364-372	receptor	object[15]|abstract[16]|abstract[18]	new[15]|new[16]|new[18]	_	_
3-14	373-374	(	_	_	_	_
3-15	375-377	ER	abstract	giv	_	_
3-16	378-379	)	_	_	_	_
3-17	380-381	,	_	_	_	_
3-18	382-394	progesterone	object|abstract[21]	new|new[21]	appos	3-21[0_21]
3-19	395-403	receptor	abstract[21]	new[21]	_	_
3-20	404-405	(	_	_	_	_
3-21	406-408	PR	abstract	giv	_	_
3-22	409-410	)	_	_	_	_
3-23	411-412	,	_	_	_	_
3-24	413-416	and	_	_	_	_
3-25	417-421	HER2	abstract|abstract[24]	new|new[24]	ana	4-1[0_24]
3-26	422-435	amplification	abstract[24]	new[24]	_	_
3-27	436-437	.	_	_	_	_

#Text=It affects primarily younger premenopausal women and tends to have higher incidences in African American women , although recent studies reported no differences in clinical outcomes between Caucasian and African American women after adjusting for socioeconomic factors .
4-1	438-440	It	abstract	giv	_	_
4-2	441-448	affects	_	_	_	_
4-3	449-458	primarily	person[26]	new[26]	coref	4-14[28_26]
4-4	459-466	younger	person[26]	new[26]	_	_
4-5	467-480	premenopausal	person[26]	new[26]	_	_
4-6	481-486	women	person[26]	new[26]	_	_
4-7	487-490	and	_	_	_	_
4-8	491-496	tends	_	_	_	_
4-9	497-499	to	_	_	_	_
4-10	500-504	have	_	_	_	_
4-11	505-511	higher	abstract[27]	new[27]	_	_
4-12	512-522	incidences	abstract[27]	new[27]	_	_
4-13	523-525	in	_	_	_	_
4-14	526-533	African	person[28]	giv[28]	coref	4-28[32_28]
4-15	534-542	American	person[28]	giv[28]	_	_
4-16	543-548	women	person[28]	giv[28]	_	_
4-17	549-550	,	_	_	_	_
4-18	551-559	although	_	_	_	_
4-19	560-566	recent	abstract[29]	new[29]	coref	14-11[94_29]
4-20	567-574	studies	abstract[29]	new[29]	_	_
4-21	575-583	reported	_	_	_	_
4-22	584-586	no	abstract[30]	new[30]	_	_
4-23	587-598	differences	abstract[30]	new[30]	_	_
4-24	599-601	in	abstract[30]	new[30]	_	_
4-25	602-610	clinical	abstract[30]|abstract[31]	new[30]|new[31]	_	_
4-26	611-619	outcomes	abstract[30]|abstract[31]	new[30]|new[31]	_	_
4-27	620-627	between	abstract[30]|abstract[31]	new[30]|new[31]	_	_
4-28	628-637	Caucasian	abstract[30]|abstract[31]|person[32]	new[30]|new[31]|giv[32]	_	_
4-29	638-641	and	abstract[30]|abstract[31]|person[32]	new[30]|new[31]|giv[32]	_	_
4-30	642-649	African	abstract[30]|abstract[31]|person[32]	new[30]|new[31]|giv[32]	_	_
4-31	650-658	American	abstract[30]|abstract[31]|person[32]	new[30]|new[31]|giv[32]	_	_
4-32	659-664	women	abstract[30]|abstract[31]|person[32]	new[30]|new[31]|giv[32]	_	_
4-33	665-670	after	_	_	_	_
4-34	671-680	adjusting	_	_	_	_
4-35	681-684	for	_	_	_	_
4-36	685-698	socioeconomic	abstract[33]	new[33]	_	_
4-37	699-706	factors	abstract[33]	new[33]	_	_
4-38	707-708	.	_	_	_	_

#Text=Currently , there are no effective targeted therapies .
5-1	709-718	Currently	_	_	_	_
5-2	719-720	,	_	_	_	_
5-3	721-726	there	_	_	_	_
5-4	727-730	are	_	_	_	_
5-5	731-733	no	abstract[34]	new[34]	coref	8-12[50_34]
5-6	734-743	effective	abstract[34]	new[34]	_	_
5-7	744-752	targeted	abstract[34]	new[34]	_	_
5-8	753-762	therapies	abstract[34]	new[34]	_	_
5-9	763-764	.	_	_	_	_

#Text=Cytotoxic chemotherapy remains the only effective therapeutic modality for this aggressive and often lethal type of breast cancer .
6-1	765-774	Cytotoxic	abstract[35]	new[35]	_	_
6-2	775-787	chemotherapy	abstract[35]	new[35]	_	_
6-3	788-795	remains	_	_	_	_
6-4	796-799	the	abstract[36]	new[36]	_	_
6-5	800-804	only	abstract[36]	new[36]	_	_
6-6	805-814	effective	abstract[36]	new[36]	_	_
6-7	815-826	therapeutic	abstract[36]	new[36]	_	_
6-8	827-835	modality	abstract[36]	new[36]	_	_
6-9	836-839	for	abstract[36]	new[36]	_	_
6-10	840-844	this	abstract[36]|abstract[37]	new[36]|new[37]	_	_
6-11	845-855	aggressive	abstract[36]|abstract[37]	new[36]|new[37]	_	_
6-12	856-859	and	abstract[36]|abstract[37]	new[36]|new[37]	_	_
6-13	860-865	often	abstract[36]|abstract[37]	new[36]|new[37]	_	_
6-14	866-872	lethal	abstract[36]|abstract[37]	new[36]|new[37]	_	_
6-15	873-877	type	abstract[36]|abstract[37]	new[36]|new[37]	_	_
6-16	878-880	of	abstract[36]|abstract[37]	new[36]|new[37]	_	_
6-17	881-887	breast	abstract[36]|abstract[37]|abstract[38]	new[36]|new[37]|giv[38]	coref	8-8[0_38]
6-18	888-894	cancer	abstract[36]|abstract[37]|abstract[38]	new[36]|new[37]|giv[38]	_	_
6-19	895-896	.	_	_	_	_

#Text=Therefore , there is an urgent need for the discovery of molecular markers and targets for the development of novel targeted therapeutics .
7-1	897-906	Therefore	_	_	_	_
7-2	907-908	,	_	_	_	_
7-3	909-914	there	_	_	_	_
7-4	915-917	is	_	_	_	_
7-5	918-920	an	abstract[39]	new[39]	coref	17-9[121_39]
7-6	921-927	urgent	abstract[39]	new[39]	_	_
7-7	928-932	need	abstract[39]	new[39]	_	_
7-8	933-936	for	abstract[39]	new[39]	_	_
7-9	937-940	the	abstract[39]|abstract[40]	new[39]|new[40]	_	_
7-10	941-950	discovery	abstract[39]|abstract[40]	new[39]|new[40]	_	_
7-11	951-953	of	abstract[39]|abstract[40]	new[39]|new[40]	_	_
7-12	954-963	molecular	abstract[39]|abstract[40]|abstract[41]	new[39]|new[40]|new[41]	coref	16-20[115_41]
7-13	964-971	markers	abstract[39]|abstract[40]|abstract[41]	new[39]|new[40]|new[41]	_	_
7-14	972-975	and	abstract[39]|abstract[40]	new[39]|new[40]	_	_
7-15	976-983	targets	abstract[39]|abstract[40]|abstract	new[39]|new[40]|new	_	_
7-16	984-987	for	abstract[39]	new[39]	_	_
7-17	988-991	the	abstract[39]|event[43]	new[39]|new[43]	_	_
7-18	992-1003	development	abstract[39]|event[43]	new[39]|new[43]	_	_
7-19	1004-1006	of	abstract[39]|event[43]	new[39]|new[43]	_	_
7-20	1007-1012	novel	abstract[39]|event[43]|abstract[44]	new[39]|new[43]|new[44]	_	_
7-21	1013-1021	targeted	abstract[39]|event[43]|abstract[44]	new[39]|new[43]|new[44]	_	_
7-22	1022-1034	therapeutics	abstract[39]|event[43]|abstract[44]	new[39]|new[43]|new[44]	_	_
7-23	1035-1036	.	_	_	_	_

#Text=Our understanding of the molecular basis of TNBC and development of effective targeted therapies has been hampered by the complexity and multifactorial etiology of the disease .
8-1	1037-1040	Our	person|abstract[46]	acc|new[46]	ana	24-1
8-2	1041-1054	understanding	abstract[46]	new[46]	_	_
8-3	1055-1057	of	abstract[46]	new[46]	_	_
8-4	1058-1061	the	abstract[46]|abstract[47]	new[46]|new[47]	_	_
8-5	1062-1071	molecular	abstract[46]|abstract[47]	new[46]|new[47]	_	_
8-6	1072-1077	basis	abstract[46]|abstract[47]	new[46]|new[47]	_	_
8-7	1078-1080	of	abstract[46]|abstract[47]	new[46]|new[47]	_	_
8-8	1081-1085	TNBC	abstract[46]|abstract[47]|abstract	new[46]|new[47]|giv	coref	8-25[53_0]
8-9	1086-1089	and	abstract[46]	new[46]	_	_
8-10	1090-1101	development	abstract[46]|abstract[49]	new[46]|new[49]	_	_
8-11	1102-1104	of	abstract[46]|abstract[49]	new[46]|new[49]	_	_
8-12	1105-1114	effective	abstract[46]|abstract[49]|abstract[50]	new[46]|new[49]|giv[50]	_	_
8-13	1115-1123	targeted	abstract[46]|abstract[49]|abstract[50]	new[46]|new[49]|giv[50]	_	_
8-14	1124-1133	therapies	abstract[46]|abstract[49]|abstract[50]	new[46]|new[49]|giv[50]	_	_
8-15	1134-1137	has	_	_	_	_
8-16	1138-1142	been	_	_	_	_
8-17	1143-1151	hampered	_	_	_	_
8-18	1152-1154	by	_	_	_	_
8-19	1155-1158	the	abstract[51]	new[51]	_	_
8-20	1159-1169	complexity	abstract[51]	new[51]	_	_
8-21	1170-1173	and	_	_	_	_
8-22	1174-1188	multifactorial	abstract[52]	new[52]	_	_
8-23	1189-1197	etiology	abstract[52]	new[52]	_	_
8-24	1198-1200	of	abstract[52]	new[52]	_	_
8-25	1201-1204	the	abstract[52]|abstract[53]	new[52]|giv[53]	coref	9-10[0_53]
8-26	1205-1212	disease	abstract[52]|abstract[53]	new[52]|giv[53]	_	_
8-27	1213-1214	.	_	_	_	_

#Text=Genes play a major role in the pathogenesis of TNBC .
9-1	1215-1220	Genes	abstract	new	coref	10-9[63_0]
9-2	1221-1225	play	_	_	_	_
9-3	1226-1227	a	abstract[55]	new[55]	coref	14-7[92_55]
9-4	1228-1233	major	abstract[55]	new[55]	_	_
9-5	1234-1238	role	abstract[55]	new[55]	_	_
9-6	1239-1241	in	abstract[55]	new[55]	_	_
9-7	1242-1245	the	abstract[55]|abstract[56]	new[55]|new[56]	coref	26-26[199_56]
9-8	1246-1258	pathogenesis	abstract[55]|abstract[56]	new[55]|new[56]	_	_
9-9	1259-1261	of	abstract[55]|abstract[56]	new[55]|new[56]	_	_
9-10	1262-1266	TNBC	abstract[55]|abstract[56]|abstract	new[55]|new[56]|giv	coref	10-4
9-11	1267-1268	.	_	_	_	_

#Text=The majority of TNBC patients carry mutations in the highly penetrant cancer susceptibility genes BRCA1 and BRCA2 .
10-1	1269-1272	The	person[59]	giv[59]	_	_
10-2	1273-1281	majority	person[59]	giv[59]	_	_
10-3	1282-1284	of	person[59]	giv[59]	_	_
10-4	1285-1289	TNBC	abstract|person[59]	giv|giv[59]	coref	10-12
10-5	1290-1298	patients	person[59]	giv[59]	_	_
10-6	1299-1304	carry	_	_	_	_
10-7	1305-1314	mutations	abstract[60]	new[60]	coref	11-9[74_60]
10-8	1315-1317	in	abstract[60]	new[60]	_	_
10-9	1318-1321	the	abstract[60]|abstract[63]|abstract[64]|abstract[65]	new[60]|giv[63]|new[64]|new[65]	coref|coref|coref	11-11[0_64]|11-11[72_65]|12-7[81_63]
10-10	1322-1328	highly	abstract[60]|abstract[63]|abstract[64]|abstract[65]	new[60]|giv[63]|new[64]|new[65]	_	_
10-11	1329-1338	penetrant	abstract[60]|abstract[63]|abstract[64]|abstract[65]	new[60]|giv[63]|new[64]|new[65]	_	_
10-12	1339-1345	cancer	abstract[60]|abstract|abstract[63]|abstract[64]|abstract[65]	new[60]|giv|giv[63]|new[64]|new[65]	coref	11-3
10-13	1346-1360	susceptibility	abstract[60]|abstract|abstract[63]|abstract[64]|abstract[65]	new[60]|new|giv[63]|new[64]|new[65]	_	_
10-14	1361-1366	genes	abstract[60]|abstract[63]|abstract[64]|abstract[65]	new[60]|giv[63]|new[64]|new[65]	_	_
10-15	1367-1372	BRCA1	abstract[60]|abstract[64]|abstract[65]	new[60]|new[64]|new[65]	_	_
10-16	1373-1376	and	abstract[60]|abstract[65]	new[60]|new[65]	_	_
10-17	1377-1382	BRCA2	abstract[60]|abstract[65]|abstract	new[60]|new[65]|new	coref	11-13
10-18	1383-1384	.	_	_	_	_

#Text=In unselected TNBC cases , the prevalence of pathogenic germline BRCA1 and BRCA2 mutations is approximately twice as high as in breast cancer overall .
11-1	1385-1387	In	_	_	_	_
11-2	1388-1398	unselected	event[68]	new[68]	_	_
11-3	1399-1403	TNBC	abstract|event[68]	giv|new[68]	coref	11-22[76_0]
11-4	1404-1409	cases	event[68]	new[68]	_	_
11-5	1410-1411	,	_	_	_	_
11-6	1412-1415	the	abstract[69]	new[69]	_	_
11-7	1416-1426	prevalence	abstract[69]	new[69]	_	_
11-8	1427-1429	of	abstract[69]	new[69]	_	_
11-9	1430-1440	pathogenic	abstract[69]|abstract[74]	new[69]|giv[74]	coref	22-40[172_74]
11-10	1441-1449	germline	abstract[69]|abstract|abstract[74]	new[69]|new|giv[74]	coref	24-9
11-11	1450-1455	BRCA1	abstract[69]|abstract|abstract[72]|abstract[74]	new[69]|giv|giv[72]|giv[74]	coref|coref	12-3|12-3[78_72]
11-12	1456-1459	and	abstract[69]|abstract[72]|abstract[74]	new[69]|giv[72]|giv[74]	_	_
11-13	1460-1465	BRCA2	abstract[69]|abstract[72]|abstract|abstract[74]	new[69]|giv[72]|giv|giv[74]	coref	12-5
11-14	1466-1475	mutations	abstract[69]|abstract[74]	new[69]|giv[74]	_	_
11-15	1476-1478	is	_	_	_	_
11-16	1479-1492	approximately	_	_	_	_
11-17	1493-1498	twice	_	_	_	_
11-18	1499-1501	as	_	_	_	_
11-19	1502-1506	high	_	_	_	_
11-20	1507-1509	as	_	_	_	_
11-21	1510-1512	in	_	_	_	_
11-22	1513-1519	breast	place|abstract[76]	new|giv[76]	coref	12-10[80_76]
11-23	1520-1526	cancer	abstract[76]	giv[76]	_	_
11-24	1527-1534	overall	abstract[76]	giv[76]	_	_
11-25	1535-1536	.	_	_	_	_

#Text=Apart from BRCA1 and BRCA2 , the rarely mutated breast cancer predisposition genes PALB2 and FANCM have been associated with TNBC .
12-1	1537-1542	Apart	_	_	_	_
12-2	1543-1547	from	_	_	_	_
12-3	1548-1553	BRCA1	abstract|abstract[78]	giv|giv[78]	_	_
12-4	1554-1557	and	abstract[78]	giv[78]	_	_
12-5	1558-1563	BRCA2	abstract[78]|abstract	giv[78]|giv	_	_
12-6	1564-1565	,	_	_	_	_
12-7	1566-1569	the	abstract[81]|abstract[82]	giv[81]|new[82]	coref	13-7[87_81]
12-8	1570-1576	rarely	abstract[81]|abstract[82]	giv[81]|new[82]	_	_
12-9	1577-1584	mutated	abstract[81]|abstract[82]	giv[81]|new[82]	_	_
12-10	1585-1591	breast	abstract[80]|abstract[81]|abstract[82]	giv[80]|giv[81]|new[82]	coref	12-21[0_80]
12-11	1592-1598	cancer	abstract[80]|abstract[81]|abstract[82]	giv[80]|giv[81]|new[82]	_	_
12-12	1599-1613	predisposition	abstract[81]|abstract[82]	giv[81]|new[82]	_	_
12-13	1614-1619	genes	abstract[81]|abstract[82]	giv[81]|new[82]	_	_
12-14	1620-1625	PALB2	abstract[82]	new[82]	_	_
12-15	1626-1629	and	_	_	_	_
12-16	1630-1635	FANCM	abstract	new	_	_
12-17	1636-1640	have	_	_	_	_
12-18	1641-1645	been	_	_	_	_
12-19	1646-1656	associated	_	_	_	_
12-20	1657-1661	with	_	_	_	_
12-21	1662-1666	TNBC	abstract	giv	coref	13-20
12-22	1667-1668	.	_	_	_	_

#Text=Multigene panel testing has also identified genes with high and moderate penetrance associated with an increased risk of developing TNBC .
13-1	1669-1678	Multigene	person[85]|abstract[86]	new[85]|new[86]	_	_
13-2	1679-1684	panel	person[85]|abstract[86]	new[85]|new[86]	_	_
13-3	1685-1692	testing	abstract[86]	new[86]	_	_
13-4	1693-1696	has	_	_	_	_
13-5	1697-1701	also	_	_	_	_
13-6	1702-1712	identified	_	_	_	_
13-7	1713-1718	genes	abstract[87]	giv[87]	coref	14-4[0_87]
13-8	1719-1723	with	abstract[87]	giv[87]	_	_
13-9	1724-1728	high	abstract[87]|abstract[88]	giv[87]|new[88]	_	_
13-10	1729-1732	and	abstract[87]|abstract[88]	giv[87]|new[88]	_	_
13-11	1733-1741	moderate	abstract[87]|abstract[88]	giv[87]|new[88]	_	_
13-12	1742-1752	penetrance	abstract[87]|abstract[88]	giv[87]|new[88]	_	_
13-13	1753-1763	associated	abstract[87]|abstract[88]	giv[87]|new[88]	_	_
13-14	1764-1768	with	abstract[87]|abstract[88]	giv[87]|new[88]	_	_
13-15	1769-1771	an	abstract[87]|abstract[88]|abstract[89]	giv[87]|new[88]|giv[89]	coref	14-16[96_89]
13-16	1772-1781	increased	abstract[87]|abstract[88]|abstract[89]	giv[87]|new[88]|giv[89]	_	_
13-17	1782-1786	risk	abstract[87]|abstract[88]|abstract[89]	giv[87]|new[88]|giv[89]	_	_
13-18	1787-1789	of	abstract[87]|abstract[88]|abstract[89]	giv[87]|new[88]|giv[89]	_	_
13-19	1790-1800	developing	abstract[87]|abstract[88]|abstract[89]	giv[87]|new[88]|giv[89]	_	_
13-20	1801-1805	TNBC	abstract[87]|abstract[88]|abstract[89]|abstract	giv[87]|new[88]|giv[89]|giv	coref	14-16
13-21	1806-1807	.	_	_	_	_

#Text=However , although genes may play a strong role , molecular epidemiology studies suggest that TNBC risk is largely determined by interactions between genes and environment .
14-1	1808-1815	However	_	_	_	_
14-2	1816-1817	,	_	_	_	_
14-3	1818-1826	although	_	_	_	_
14-4	1827-1832	genes	abstract	giv	coref	14-24
14-5	1833-1836	may	_	_	_	_
14-6	1837-1841	play	_	_	_	_
14-7	1842-1843	a	abstract[92]	giv[92]	_	_
14-8	1844-1850	strong	abstract[92]	giv[92]	_	_
14-9	1851-1855	role	abstract[92]	giv[92]	_	_
14-10	1856-1857	,	_	_	_	_
14-11	1858-1867	molecular	abstract[93]|abstract[94]	new[93]|giv[94]	coref	21-4[150_94]
14-12	1868-1880	epidemiology	abstract[93]|abstract[94]	new[93]|giv[94]	_	_
14-13	1881-1888	studies	abstract[94]	giv[94]	_	_
14-14	1889-1896	suggest	_	_	_	_
14-15	1897-1901	that	_	_	_	_
14-16	1902-1906	TNBC	abstract|abstract[96]	giv|giv[96]	coref|coref	15-13|21-18[154_96]
14-17	1907-1911	risk	abstract[96]	giv[96]	_	_
14-18	1912-1914	is	_	_	_	_
14-19	1915-1922	largely	_	_	_	_
14-20	1923-1933	determined	_	_	_	_
14-21	1934-1936	by	_	_	_	_
14-22	1937-1949	interactions	abstract[97]	new[97]	coref	24-4[177_97]
14-23	1950-1957	between	abstract[97]	new[97]	_	_
14-24	1958-1963	genes	abstract[97]|abstract|abstract[99]	new[97]|giv|giv[99]	coref|coref	14-24[99_0]|16-10[113_99]
14-25	1964-1967	and	abstract[97]|abstract[99]	new[97]|giv[99]	_	_
14-26	1968-1979	environment	abstract[97]|abstract[99]|abstract	new[97]|giv[99]|new	_	_
14-27	1980-1981	.	_	_	_	_

#Text=Increased attention has focused on epigenetic variation such as DNA methylation and TNBC because enduring epigenetic landmarks define the tumor microenvironment .
15-1	1982-1991	Increased	abstract[101]	new[101]	_	_
15-2	1992-2001	attention	abstract[101]	new[101]	_	_
15-3	2002-2005	has	_	_	_	_
15-4	2006-2013	focused	_	_	_	_
15-5	2014-2016	on	_	_	_	_
15-6	2017-2027	epigenetic	abstract[102]	new[102]	coref	17-19[123_102]
15-7	2028-2037	variation	abstract[102]	new[102]	_	_
15-8	2038-2042	such	abstract[102]	new[102]	_	_
15-9	2043-2045	as	abstract[102]	new[102]	_	_
15-10	2046-2049	DNA	abstract[102]|abstract|abstract[104]	new[102]|new|new[104]	coref|coref	16-4|16-4[110_104]
15-11	2050-2061	methylation	abstract[102]|abstract[104]	new[102]|new[104]	_	_
15-12	2062-2065	and	abstract[102]	new[102]	_	_
15-13	2066-2070	TNBC	abstract[102]|abstract	new[102]|giv	coref	17-31
15-14	2071-2078	because	_	_	_	_
15-15	2079-2087	enduring	abstract[106]	new[106]	_	_
15-16	2088-2098	epigenetic	abstract[106]	new[106]	_	_
15-17	2099-2108	landmarks	abstract[106]	new[106]	_	_
15-18	2109-2115	define	_	_	_	_
15-19	2116-2119	the	abstract[108]	new[108]	_	_
15-20	2120-2125	tumor	abstract|abstract[108]	new|new[108]	coref	22-9
15-21	2126-2142	microenvironment	abstract[108]	new[108]	_	_
15-22	2143-2144	.	_	_	_	_

#Text=Moreover , because DNA methylation regulates gene expression , aberrant methylated genes could serve as complementary diagnostic tools , prognostic markers and predictors of response to treatment .
16-1	2145-2153	Moreover	_	_	_	_
16-2	2154-2155	,	_	_	_	_
16-3	2156-2163	because	_	_	_	_
16-4	2164-2167	DNA	abstract|abstract[110]	giv|giv[110]	coref|coref	25-22|25-22[189_110]
16-5	2168-2179	methylation	abstract[110]	giv[110]	_	_
16-6	2180-2189	regulates	_	_	_	_
16-7	2190-2194	gene	abstract|abstract[112]	new|giv[112]	coref|coref	20-25|20-25[146_112]
16-8	2195-2205	expression	abstract[112]	giv[112]	_	_
16-9	2206-2207	,	_	_	_	_
16-10	2208-2216	aberrant	abstract[113]	giv[113]	coref	24-7[178_113]
16-11	2217-2227	methylated	abstract[113]	giv[113]	_	_
16-12	2228-2233	genes	abstract[113]	giv[113]	_	_
16-13	2234-2239	could	_	_	_	_
16-14	2240-2245	serve	_	_	_	_
16-15	2246-2248	as	_	_	_	_
16-16	2249-2262	complementary	abstract[114]	new[114]	_	_
16-17	2263-2273	diagnostic	abstract[114]	new[114]	_	_
16-18	2274-2279	tools	abstract[114]	new[114]	_	_
16-19	2280-2281	,	_	_	_	_
16-20	2282-2292	prognostic	abstract[115]	giv[115]	coref	20-12[142_115]
16-21	2293-2300	markers	abstract[115]	giv[115]	_	_
16-22	2301-2304	and	_	_	_	_
16-23	2305-2315	predictors	person[116]	new[116]	_	_
16-24	2316-2318	of	person[116]	new[116]	_	_
16-25	2319-2327	response	person[116]|event[117]	new[116]|new[117]	_	_
16-26	2328-2330	to	person[116]|event[117]	new[116]|new[117]	_	_
16-27	2331-2340	treatment	person[116]|event[117]|event	new[116]|new[117]|new	_	_
16-28	2341-2342	.	_	_	_	_

#Text=Thus , a critical knowledge gap , and an unmet medical need , is understanding the interplay between genetic ( both germline and somatic ) variation and epigenomic variation in TNBC .
17-1	2343-2347	Thus	_	_	_	_
17-2	2348-2349	,	_	_	_	_
17-3	2350-2351	a	abstract[120]	new[120]	_	_
17-4	2352-2360	critical	abstract[120]	new[120]	_	_
17-5	2361-2370	knowledge	abstract|abstract[120]	new|new[120]	_	_
17-6	2371-2374	gap	abstract[120]	new[120]	_	_
17-7	2375-2376	,	_	_	_	_
17-8	2377-2380	and	_	_	_	_
17-9	2381-2383	an	abstract[121]	giv[121]	_	_
17-10	2384-2389	unmet	abstract[121]	giv[121]	_	_
17-11	2390-2397	medical	abstract[121]	giv[121]	_	_
17-12	2398-2402	need	abstract[121]	giv[121]	_	_
17-13	2403-2404	,	_	_	_	_
17-14	2405-2407	is	_	_	_	_
17-15	2408-2421	understanding	_	_	_	_
17-16	2422-2425	the	abstract[122]	new[122]	coref	25-27[191_122]
17-17	2426-2435	interplay	abstract[122]	new[122]	_	_
17-18	2436-2443	between	abstract[122]	new[122]	_	_
17-19	2444-2451	genetic	abstract[122]|abstract[123]|abstract[124]	new[122]|giv[123]|giv[124]	coref|coref	17-19[124_123]|17-28[125_124]
17-20	2452-2453	(	abstract[122]|abstract[123]|abstract[124]	new[122]|giv[123]|giv[124]	_	_
17-21	2454-2458	both	abstract[122]|abstract[123]|abstract[124]	new[122]|giv[123]|giv[124]	_	_
17-22	2459-2467	germline	abstract[122]|abstract[123]|abstract[124]	new[122]|giv[123]|giv[124]	_	_
17-23	2468-2471	and	abstract[122]|abstract[123]|abstract[124]	new[122]|giv[123]|giv[124]	_	_
17-24	2472-2479	somatic	abstract[122]|abstract[123]|abstract[124]	new[122]|giv[123]|giv[124]	_	_
17-25	2480-2481	)	abstract[122]|abstract[123]|abstract[124]	new[122]|giv[123]|giv[124]	_	_
17-26	2482-2491	variation	abstract[122]|abstract[123]|abstract[124]	new[122]|giv[123]|giv[124]	_	_
17-27	2492-2495	and	abstract[122]|abstract[124]	new[122]|giv[124]	_	_
17-28	2496-2506	epigenomic	abstract[122]|abstract[124]|abstract[125]	new[122]|giv[124]|giv[125]	coref	25-8[187_125]
17-29	2507-2516	variation	abstract[122]|abstract[124]|abstract[125]	new[122]|giv[124]|giv[125]	_	_
17-30	2517-2519	in	abstract[122]|abstract[124]|abstract[125]	new[122]|giv[124]|giv[125]	_	_
17-31	2520-2524	TNBC	abstract[122]|abstract[124]|abstract[125]|abstract	new[122]|giv[124]|giv[125]|giv	coref	18-12
17-32	2525-2526	.	_	_	_	_

#Text=Advances in microarray technology have enabled molecular classification of subtypes of TNBC .
18-1	2527-2535	Advances	abstract[127]	new[127]	_	_
18-2	2536-2538	in	abstract[127]	new[127]	_	_
18-3	2539-2549	microarray	abstract[127]|place|abstract[129]	new[127]|new|new[129]	_	_
18-4	2550-2560	technology	abstract[127]|abstract[129]	new[127]|new[129]	_	_
18-5	2561-2565	have	_	_	_	_
18-6	2566-2573	enabled	_	_	_	_
18-7	2574-2583	molecular	abstract[130]	new[130]	_	_
18-8	2584-2598	classification	abstract[130]	new[130]	_	_
18-9	2599-2601	of	abstract[130]	new[130]	_	_
18-10	2602-2610	subtypes	abstract[130]|abstract[131]	new[130]|new[131]	_	_
18-11	2611-2613	of	abstract[130]|abstract[131]	new[130]|new[131]	_	_
18-12	2614-2618	TNBC	abstract[130]|abstract[131]|abstract	new[130]|new[131]|giv	coref	20-28[147_0]
18-13	2619-2620	.	_	_	_	_

#Text=At least , several clinically validated prognostic assays including the Prosigna PAM50 , MammaPrint and Oncotype DX , have been developed using transcription profiling .
19-1	2621-2623	At	_	_	_	_
19-2	2624-2629	least	_	_	_	_
19-3	2630-2631	,	_	_	_	_
19-4	2632-2639	several	abstract[133]	new[133]	_	_
19-5	2640-2650	clinically	abstract[133]	new[133]	_	_
19-6	2651-2660	validated	abstract[133]	new[133]	_	_
19-7	2661-2671	prognostic	abstract[133]	new[133]	_	_
19-8	2672-2678	assays	abstract[133]	new[133]	_	_
19-9	2679-2688	including	abstract[133]	new[133]	_	_
19-10	2689-2692	the	abstract[133]|abstract[135]	new[133]|new[135]	_	_
19-11	2693-2701	Prosigna	abstract[133]|place|abstract[135]	new[133]|new|new[135]	_	_
19-12	2702-2707	PAM50	abstract[133]|abstract[135]	new[133]|new[135]	_	_
19-13	2708-2709	,	abstract[133]	new[133]	_	_
19-14	2710-2720	MammaPrint	abstract[133]|abstract	new[133]|new	_	_
19-15	2721-2724	and	abstract[133]	new[133]	_	_
19-16	2725-2733	Oncotype	abstract[133]|abstract|abstract[138]	new[133]|new|new[138]	_	_
19-17	2734-2736	DX	abstract[133]|abstract[138]	new[133]|new[138]	_	_
19-18	2737-2738	,	_	_	_	_
19-19	2739-2743	have	_	_	_	_
19-20	2744-2748	been	_	_	_	_
19-21	2749-2758	developed	_	_	_	_
19-22	2759-2764	using	_	_	_	_
19-23	2765-2778	transcription	abstract|abstract[140]	new|new[140]	_	_
19-24	2779-2788	profiling	abstract[140]	new[140]	_	_
19-25	2789-2790	.	_	_	_	_

#Text=However , although these primary analyses have been successful in identifying prognostic markers , they have been unsuccessful in establishing the causal association between gene expression and the disease .
20-1	2791-2798	However	_	_	_	_
20-2	2799-2800	,	_	_	_	_
20-3	2801-2809	although	_	_	_	_
20-4	2810-2815	these	abstract[141]	new[141]	_	_
20-5	2816-2823	primary	abstract[141]	new[141]	_	_
20-6	2824-2832	analyses	abstract[141]	new[141]	_	_
20-7	2833-2837	have	_	_	_	_
20-8	2838-2842	been	_	_	_	_
20-9	2843-2853	successful	_	_	_	_
20-10	2854-2856	in	_	_	_	_
20-11	2857-2868	identifying	_	_	_	_
20-12	2869-2879	prognostic	abstract[142]	giv[142]	ana	20-15[0_142]
20-13	2880-2887	markers	abstract[142]	giv[142]	_	_
20-14	2888-2889	,	_	_	_	_
20-15	2890-2894	they	abstract	giv	_	_
20-16	2895-2899	have	_	_	_	_
20-17	2900-2904	been	_	_	_	_
20-18	2905-2917	unsuccessful	_	_	_	_
20-19	2918-2920	in	_	_	_	_
20-20	2921-2933	establishing	_	_	_	_
20-21	2934-2937	the	abstract[144]	new[144]	coref	21-4[149_144]
20-22	2938-2944	causal	abstract[144]	new[144]	_	_
20-23	2945-2956	association	abstract[144]	new[144]	_	_
20-24	2957-2964	between	abstract[144]	new[144]	_	_
20-25	2965-2969	gene	abstract[144]|abstract|abstract[146]	new[144]|giv|giv[146]	coref|coref	25-12|25-13[0_146]
20-26	2970-2980	expression	abstract[144]|abstract[146]	new[144]|giv[146]	_	_
20-27	2981-2984	and	abstract[144]	new[144]	_	_
20-28	2985-2988	the	abstract[144]|abstract[147]	new[144]|giv[147]	coref	21-23[0_147]
20-29	2989-2996	disease	abstract[144]|abstract[147]	new[144]|giv[147]	_	_
20-30	2997-2998	.	_	_	_	_

#Text=High-throughput genotyping using genome-wide association studies ( GWAS ) has enabled discovery of genetic variants associated with an increased risk of developing TNBC .
21-1	2999-3014	High-throughput	abstract[148]	new[148]	_	_
21-2	3015-3025	genotyping	abstract[148]	new[148]	_	_
21-3	3026-3031	using	abstract[148]	new[148]	_	_
21-4	3032-3043	genome-wide	abstract[148]|abstract[149]|abstract[150]	new[148]|giv[149]|giv[150]	appos	21-8[0_150]
21-5	3044-3055	association	abstract[148]|abstract[149]|abstract[150]	new[148]|giv[149]|giv[150]	_	_
21-6	3056-3063	studies	abstract[148]|abstract[150]	new[148]|giv[150]	_	_
21-7	3064-3065	(	_	_	_	_
21-8	3066-3070	GWAS	abstract	giv	coref	30-12
21-9	3071-3072	)	_	_	_	_
21-10	3073-3076	has	_	_	_	_
21-11	3077-3084	enabled	_	_	_	_
21-12	3085-3094	discovery	abstract[152]	new[152]	_	_
21-13	3095-3097	of	abstract[152]	new[152]	_	_
21-14	3098-3105	genetic	abstract[152]|abstract[153]	new[152]|new[153]	_	_
21-15	3106-3114	variants	abstract[152]|abstract[153]	new[152]|new[153]	_	_
21-16	3115-3125	associated	abstract[152]|abstract[153]	new[152]|new[153]	_	_
21-17	3126-3130	with	abstract[152]|abstract[153]	new[152]|new[153]	_	_
21-18	3131-3133	an	abstract[152]|abstract[153]|abstract[154]	new[152]|new[153]|giv[154]	_	_
21-19	3134-3143	increased	abstract[152]|abstract[153]|abstract[154]	new[152]|new[153]|giv[154]	_	_
21-20	3144-3148	risk	abstract[152]|abstract[153]|abstract[154]	new[152]|new[153]|giv[154]	_	_
21-21	3149-3151	of	abstract[152]|abstract[153]|abstract[154]	new[152]|new[153]|giv[154]	_	_
21-22	3152-3162	developing	abstract[152]|abstract[153]|abstract[154]	new[152]|new[153]|giv[154]	_	_
21-23	3163-3167	TNBC	abstract[152]|abstract[153]|abstract[154]|abstract	new[152]|new[153]|giv[154]|giv	coref	22-19
21-24	3168-3169	.	_	_	_	_

#Text=The recent surge of next generation sequencing of tumor genomes by large multicenter projects , such as The Cancer Genome Atlas ( TCGA ) and the International Cancer Genome Consortium ( ICGC ) , have generated comprehensive catalogues of somatic mutations associated with TNBC .
22-1	3170-3173	The	event[156]	new[156]	_	_
22-2	3174-3180	recent	event[156]	new[156]	_	_
22-3	3181-3186	surge	event[156]	new[156]	_	_
22-4	3187-3189	of	event[156]	new[156]	_	_
22-5	3190-3194	next	event[156]|abstract[157]|abstract[158]	new[156]|new[157]|new[158]	_	_
22-6	3195-3205	generation	event[156]|abstract[157]|abstract[158]	new[156]|new[157]|new[158]	_	_
22-7	3206-3216	sequencing	event[156]|abstract[158]	new[156]|new[158]	_	_
22-8	3217-3219	of	event[156]|abstract[158]	new[156]|new[158]	_	_
22-9	3220-3225	tumor	event[156]|abstract[158]|abstract|object[160]	new[156]|new[158]|giv|new[160]	_	_
22-10	3226-3233	genomes	event[156]|abstract[158]|object[160]	new[156]|new[158]|new[160]	_	_
22-11	3234-3236	by	event[156]	new[156]	_	_
22-12	3237-3242	large	event[156]|abstract[162]	new[156]|new[162]	_	_
22-13	3243-3254	multicenter	event[156]|person|abstract[162]	new[156]|new|new[162]	_	_
22-14	3255-3263	projects	event[156]|abstract[162]	new[156]|new[162]	_	_
22-15	3264-3265	,	event[156]|abstract[162]	new[156]|new[162]	_	_
22-16	3266-3270	such	event[156]|abstract[162]	new[156]|new[162]	_	_
22-17	3271-3273	as	event[156]|abstract[162]	new[156]|new[162]	_	_
22-18	3274-3277	The	event[156]|abstract[162]|abstract[165]	new[156]|new[162]|new[165]	appos	22-23[0_165]
22-19	3278-3284	Cancer	event[156]|abstract[162]|abstract|abstract[165]	new[156]|new[162]|giv|new[165]	coref	22-28
22-20	3285-3291	Genome	event[156]|abstract[162]|abstract|abstract[165]	new[156]|new[162]|new|new[165]	coref	22-28[168_0]
22-21	3292-3297	Atlas	event[156]|abstract[162]|abstract[165]	new[156]|new[162]|new[165]	_	_
22-22	3298-3299	(	_	_	_	_
22-23	3300-3304	TCGA	abstract	giv	coref	30-21
22-24	3305-3306	)	_	_	_	_
22-25	3307-3310	and	_	_	_	_
22-26	3311-3314	the	organization[169]	new[169]	_	_
22-27	3315-3328	International	organization[169]	new[169]	_	_
22-28	3329-3335	Cancer	abstract|abstract[168]|organization[169]	giv|giv[168]|new[169]	coref	22-44
22-29	3336-3342	Genome	abstract[168]|organization[169]	giv[168]|new[169]	_	_
22-30	3343-3353	Consortium	organization[169]	new[169]	_	_
22-31	3354-3355	(	_	_	_	_
22-32	3356-3360	ICGC	abstract	new	_	_
22-33	3361-3362	)	_	_	_	_
22-34	3363-3364	,	_	_	_	_
22-35	3365-3369	have	_	_	_	_
22-36	3370-3379	generated	_	_	_	_
22-37	3380-3393	comprehensive	abstract[171]	new[171]	_	_
22-38	3394-3404	catalogues	abstract[171]	new[171]	_	_
22-39	3405-3407	of	abstract[171]	new[171]	_	_
22-40	3408-3415	somatic	abstract[171]|abstract[172]	new[171]|giv[172]	coref	24-11[180_172]
22-41	3416-3425	mutations	abstract[171]|abstract[172]	new[171]|giv[172]	_	_
22-42	3426-3436	associated	abstract[171]|abstract[172]	new[171]|giv[172]	_	_
22-43	3437-3441	with	abstract[171]|abstract[172]	new[171]|giv[172]	_	_
22-44	3442-3446	TNBC	abstract[171]|abstract[172]|abstract	new[171]|giv[172]|giv	coref	24-14
22-45	3447-3448	.	_	_	_	_

#Text=The clonal and mutational spectrum of primary TNBCs have also been characterized .
23-1	3449-3452	The	abstract[174]	new[174]	_	_
23-2	3453-3459	clonal	abstract[174]	new[174]	_	_
23-3	3460-3463	and	abstract[174]	new[174]	_	_
23-4	3464-3474	mutational	abstract[174]	new[174]	_	_
23-5	3475-3483	spectrum	abstract[174]	new[174]	_	_
23-6	3484-3486	of	abstract[174]	new[174]	_	_
23-7	3487-3494	primary	abstract[174]|abstract[175]	new[174]|new[175]	_	_
23-8	3495-3500	TNBCs	abstract[174]|abstract[175]	new[174]|new[175]	_	_
23-9	3501-3505	have	_	_	_	_
23-10	3506-3510	also	_	_	_	_
23-11	3511-3515	been	_	_	_	_
23-12	3516-3529	characterized	_	_	_	_
23-13	3530-3531	.	_	_	_	_

#Text=We recently reported oncogenic interactions between genes containing germline and somatic mutations in TNBC .
24-1	3532-3534	We	person	giv	ana	28-1
24-2	3535-3543	recently	_	_	_	_
24-3	3544-3552	reported	_	_	_	_
24-4	3553-3562	oncogenic	abstract[177]	giv[177]	coref	27-29[208_177]
24-5	3563-3575	interactions	abstract[177]	giv[177]	_	_
24-6	3576-3583	between	abstract[177]	giv[177]	_	_
24-7	3584-3589	genes	abstract[177]|abstract[178]	giv[177]|giv[178]	_	_
24-8	3590-3600	containing	abstract[177]|abstract[178]	giv[177]|giv[178]	_	_
24-9	3601-3609	germline	abstract[177]|abstract[178]|abstract	giv[177]|giv[178]|giv	coref	25-8
24-10	3610-3613	and	abstract[177]|abstract[178]	giv[177]|giv[178]	_	_
24-11	3614-3621	somatic	abstract[177]|abstract[178]|abstract[180]	giv[177]|giv[178]|giv[180]	_	_
24-12	3622-3631	mutations	abstract[177]|abstract[178]|abstract[180]	giv[177]|giv[178]|giv[180]	_	_
24-13	3632-3634	in	abstract[177]|abstract[178]	giv[177]|giv[178]	_	_
24-14	3635-3639	TNBC	abstract[177]|abstract[178]|abstract	giv[177]|giv[178]|giv	coref	25-35
24-15	3640-3641	.	_	_	_	_

#Text=However , to date , information on germline , somatic and gene expression variation has not been leveraged and integrated with DNA methylation data to map the interplay between genetic and epigenetic variation in TNBC .
25-1	3642-3649	However	_	_	_	_
25-2	3650-3651	,	_	_	_	_
25-3	3652-3654	to	_	_	_	_
25-4	3655-3659	date	time	new	_	_
25-5	3660-3661	,	_	_	_	_
25-6	3662-3673	information	abstract[183]	new[183]	coref	30-7[227_183]
25-7	3674-3676	on	abstract[183]	new[183]	_	_
25-8	3677-3685	germline	abstract[183]|abstract|abstract[187]	new[183]|giv|giv[187]	coref|coref	25-30[192_187]|30-9
25-9	3686-3687	,	abstract[183]|abstract[187]	new[183]|giv[187]	_	_
25-10	3688-3695	somatic	abstract[183]|abstract[187]	new[183]|giv[187]	_	_
25-11	3696-3699	and	abstract[183]|abstract[187]	new[183]|giv[187]	_	_
25-12	3700-3704	gene	abstract[183]|abstract|abstract[187]	new[183]|giv|giv[187]	coref	30-23
25-13	3705-3715	expression	abstract[183]|abstract|abstract[187]	new[183]|giv|giv[187]	coref	30-23[235_0]
25-14	3716-3725	variation	abstract[183]|abstract[187]	new[183]|giv[187]	_	_
25-15	3726-3729	has	_	_	_	_
25-16	3730-3733	not	_	_	_	_
25-17	3734-3738	been	_	_	_	_
25-18	3739-3748	leveraged	_	_	_	_
25-19	3749-3752	and	_	_	_	_
25-20	3753-3763	integrated	_	_	_	_
25-21	3764-3768	with	_	_	_	_
25-22	3769-3772	DNA	abstract|abstract[189]|abstract[190]	giv|giv[189]|new[190]	_	_
25-23	3773-3784	methylation	abstract[189]|abstract[190]	giv[189]|new[190]	_	_
25-24	3785-3789	data	abstract[190]	new[190]	_	_
25-25	3790-3792	to	_	_	_	_
25-26	3793-3796	map	_	_	_	_
25-27	3797-3800	the	abstract[191]	giv[191]	coref	28-9[213_191]
25-28	3801-3810	interplay	abstract[191]	giv[191]	_	_
25-29	3811-3818	between	abstract[191]	giv[191]	_	_
25-30	3819-3826	genetic	abstract[191]|abstract[192]	giv[191]|giv[192]	coref	28-13[214_192]
25-31	3827-3830	and	abstract[191]|abstract[192]	giv[191]|giv[192]	_	_
25-32	3831-3841	epigenetic	abstract[191]|abstract[192]	giv[191]|giv[192]	_	_
25-33	3842-3851	variation	abstract[191]|abstract[192]	giv[191]|giv[192]	_	_
25-34	3852-3854	in	abstract[191]|abstract[192]	giv[191]|giv[192]	_	_
25-35	3855-3859	TNBC	abstract[191]|abstract[192]|abstract	giv[191]|giv[192]|giv	coref	26-26
25-36	3860-3861	.	_	_	_	_

#Text=This limited progress must be balanced against the recognition that genomic and epigenomic alterations have long been considered as two separate molecular mechanisms participating in TNBC pathogenesis .
26-1	3862-3866	This	abstract[194]	new[194]	_	_
26-2	3867-3874	limited	abstract[194]	new[194]	_	_
26-3	3875-3883	progress	abstract[194]	new[194]	_	_
26-4	3884-3888	must	_	_	_	_
26-5	3889-3891	be	_	_	_	_
26-6	3892-3900	balanced	_	_	_	_
26-7	3901-3908	against	_	_	_	_
26-8	3909-3912	the	abstract[195]	new[195]	_	_
26-9	3913-3924	recognition	abstract[195]	new[195]	_	_
26-10	3925-3929	that	abstract[195]	new[195]	_	_
26-11	3930-3937	genomic	abstract[195]|abstract[196]	new[195]|new[196]	_	_
26-12	3938-3941	and	abstract[195]|abstract[196]	new[195]|new[196]	_	_
26-13	3942-3952	epigenomic	abstract[195]|abstract[196]	new[195]|new[196]	_	_
26-14	3953-3964	alterations	abstract[195]|abstract[196]	new[195]|new[196]	_	_
26-15	3965-3969	have	abstract[195]	new[195]	_	_
26-16	3970-3974	long	abstract[195]	new[195]	_	_
26-17	3975-3979	been	abstract[195]	new[195]	_	_
26-18	3980-3990	considered	abstract[195]	new[195]	_	_
26-19	3991-3993	as	abstract[195]	new[195]	_	_
26-20	3994-3997	two	abstract[195]|abstract[197]	new[195]|new[197]	_	_
26-21	3998-4006	separate	abstract[195]|abstract[197]	new[195]|new[197]	_	_
26-22	4007-4016	molecular	abstract[195]|abstract[197]	new[195]|new[197]	_	_
26-23	4017-4027	mechanisms	abstract[195]|abstract[197]	new[195]|new[197]	_	_
26-24	4028-4041	participating	abstract[195]|abstract[197]	new[195]|new[197]	_	_
26-25	4042-4044	in	abstract[195]|abstract[197]	new[195]|new[197]	_	_
26-26	4045-4049	TNBC	abstract[195]|abstract[197]|abstract|abstract[199]	new[195]|new[197]|giv|giv[199]	coref	27-32
26-27	4050-4062	pathogenesis	abstract[195]|abstract[197]|abstract[199]	new[195]|new[197]|giv[199]	_	_
26-28	4063-4064	.	_	_	_	_

#Text=The objective of this investigation is to deconvolute the genomic and epigenomic interaction landscape , and to discover and characterize the molecular networks and signaling pathways perturbed by these interactions in TNBC .
27-1	4065-4068	The	abstract[200]	new[200]	_	_
27-2	4069-4078	objective	abstract[200]	new[200]	_	_
27-3	4079-4081	of	abstract[200]	new[200]	_	_
27-4	4082-4086	this	abstract[200]|abstract[201]	new[200]|new[201]	_	_
27-5	4087-4100	investigation	abstract[200]|abstract[201]	new[200]|new[201]	_	_
27-6	4101-4103	is	_	_	_	_
27-7	4104-4106	to	_	_	_	_
27-8	4107-4118	deconvolute	_	_	_	_
27-9	4119-4122	the	abstract[203]	new[203]	_	_
27-10	4123-4130	genomic	abstract[203]	new[203]	_	_
27-11	4131-4134	and	abstract[203]	new[203]	_	_
27-12	4135-4145	epigenomic	abstract[203]	new[203]	_	_
27-13	4146-4157	interaction	abstract|abstract[203]	new|new[203]	_	_
27-14	4158-4167	landscape	abstract[203]	new[203]	_	_
27-15	4168-4169	,	_	_	_	_
27-16	4170-4173	and	_	_	_	_
27-17	4174-4176	to	_	_	_	_
27-18	4177-4185	discover	_	_	_	_
27-19	4186-4189	and	_	_	_	_
27-20	4190-4202	characterize	_	_	_	_
27-21	4203-4206	the	abstract[204]|abstract[205]	new[204]|new[205]	coref|coref	29-15[220_204]|29-15[221_205]
27-22	4207-4216	molecular	abstract[204]|abstract[205]	new[204]|new[205]	_	_
27-23	4217-4225	networks	abstract[204]|abstract[205]	new[204]|new[205]	_	_
27-24	4226-4229	and	abstract[205]	new[205]	_	_
27-25	4230-4239	signaling	abstract[205]|abstract|abstract[207]	new[205]|new|new[207]	coref|coref	29-19|29-19[223_207]
27-26	4240-4248	pathways	abstract[205]|abstract[207]	new[205]|new[207]	_	_
27-27	4249-4258	perturbed	abstract[205]|abstract[207]	new[205]|new[207]	_	_
27-28	4259-4261	by	abstract[205]|abstract[207]	new[205]|new[207]	_	_
27-29	4262-4267	these	abstract[205]|abstract[207]|abstract[208]	new[205]|new[207]|giv[208]	_	_
27-30	4268-4280	interactions	abstract[205]|abstract[207]|abstract[208]	new[205]|new[207]|giv[208]	_	_
27-31	4281-4283	in	abstract[205]|abstract[207]	new[205]|new[207]	_	_
27-32	4284-4288	TNBC	abstract[205]|abstract[207]|abstract	new[205]|new[207]|giv	coref	28-6
27-33	4289-4290	.	_	_	_	_

#Text=Our working hypothesis was that TNBC originates from a complex interplay between genomic ( both germline and somatic ) variation and epigenomic variations .
28-1	4291-4294	Our	person|abstract[211]	giv|new[211]	ana	29-1
28-2	4295-4302	working	abstract[211]	new[211]	_	_
28-3	4303-4313	hypothesis	abstract[211]	new[211]	_	_
28-4	4314-4317	was	_	_	_	_
28-5	4318-4322	that	_	_	_	_
28-6	4323-4327	TNBC	abstract	giv	coref	29-27
28-7	4328-4338	originates	_	_	_	_
28-8	4339-4343	from	_	_	_	_
28-9	4344-4345	a	abstract[213]	giv[213]	_	_
28-10	4346-4353	complex	abstract[213]	giv[213]	_	_
28-11	4354-4363	interplay	abstract[213]	giv[213]	_	_
28-12	4364-4371	between	abstract[213]	giv[213]	_	_
28-13	4372-4379	genomic	abstract[213]|abstract[214]|abstract[215]	giv[213]|giv[214]|giv[215]	coref|coref	28-13[215_214]|30-9[229_215]
28-14	4380-4381	(	abstract[213]|abstract[214]|abstract[215]	giv[213]|giv[214]|giv[215]	_	_
28-15	4382-4386	both	abstract[213]|abstract[214]|abstract[215]	giv[213]|giv[214]|giv[215]	_	_
28-16	4387-4395	germline	abstract[213]|abstract[214]|abstract[215]	giv[213]|giv[214]|giv[215]	_	_
28-17	4396-4399	and	abstract[213]|abstract[214]|abstract[215]	giv[213]|giv[214]|giv[215]	_	_
28-18	4400-4407	somatic	abstract[213]|abstract[214]|abstract[215]	giv[213]|giv[214]|giv[215]	_	_
28-19	4408-4409	)	abstract[213]|abstract[214]|abstract[215]	giv[213]|giv[214]|giv[215]	_	_
28-20	4410-4419	variation	abstract[213]|abstract[214]|abstract[215]	giv[213]|giv[214]|giv[215]	_	_
28-21	4420-4423	and	abstract[213]|abstract[215]	giv[213]|giv[215]	_	_
28-22	4424-4434	epigenomic	abstract[213]|abstract[215]|abstract[216]	giv[213]|giv[215]|new[216]	_	_
28-23	4435-4445	variations	abstract[213]|abstract[215]|abstract[216]	giv[213]|giv[215]|new[216]	_	_
28-24	4446-4447	.	_	_	_	_

#Text=We further hypothesized that these complex arrays of interacting genomic and epigenomic factors affect entire molecular networks and signaling pathways which , in turn , drive TNBC .
29-1	4448-4450	We	person	giv	ana	30-1
29-2	4451-4458	further	_	_	_	_
29-3	4459-4471	hypothesized	_	_	_	_
29-4	4472-4476	that	_	_	_	_
29-5	4477-4482	these	place[218]	new[218]	_	_
29-6	4483-4490	complex	place[218]	new[218]	_	_
29-7	4491-4497	arrays	place[218]	new[218]	_	_
29-8	4498-4500	of	place[218]	new[218]	_	_
29-9	4501-4512	interacting	place[218]|abstract[219]	new[218]|new[219]	_	_
29-10	4513-4520	genomic	place[218]|abstract[219]	new[218]|new[219]	_	_
29-11	4521-4524	and	place[218]|abstract[219]	new[218]|new[219]	_	_
29-12	4525-4535	epigenomic	place[218]|abstract[219]	new[218]|new[219]	_	_
29-13	4536-4543	factors	place[218]|abstract[219]	new[218]|new[219]	_	_
29-14	4544-4550	affect	_	_	_	_
29-15	4551-4557	entire	abstract[220]|abstract[221]	giv[220]|giv[221]	_	_
29-16	4558-4567	molecular	abstract[220]|abstract[221]	giv[220]|giv[221]	_	_
29-17	4568-4576	networks	abstract[220]|abstract[221]	giv[220]|giv[221]	_	_
29-18	4577-4580	and	abstract[221]	giv[221]	_	_
29-19	4581-4590	signaling	abstract[221]|abstract|abstract[223]	giv[221]|giv|giv[223]	_	_
29-20	4591-4599	pathways	abstract[221]|abstract[223]	giv[221]|giv[223]	_	_
29-21	4600-4605	which	abstract[221]|abstract[223]	giv[221]|giv[223]	_	_
29-22	4606-4607	,	abstract[221]|abstract[223]	giv[221]|giv[223]	_	_
29-23	4608-4610	in	abstract[221]|abstract[223]	giv[221]|giv[223]	_	_
29-24	4611-4615	turn	abstract[221]|abstract[223]	giv[221]|giv[223]	_	_
29-25	4616-4617	,	abstract[221]|abstract[223]	giv[221]|giv[223]	_	_
29-26	4618-4623	drive	abstract[221]|abstract[223]	giv[221]|giv[223]	_	_
29-27	4624-4628	TNBC	abstract[221]|abstract[223]|abstract	giv[221]|giv[223]|giv	_	_
29-28	4629-4630	.	_	_	_	_

#Text=We addressed these hypotheses by integrating information on germline variation from GWAS with information on somatic and epigenomic variation from TCGA using gene expression as the intermediated phenotype .
30-1	4631-4633	We	person	giv	_	_
30-2	4634-4643	addressed	_	_	_	_
30-3	4644-4649	these	abstract[226]	new[226]	_	_
30-4	4650-4660	hypotheses	abstract[226]	new[226]	_	_
30-5	4661-4663	by	_	_	_	_
30-6	4664-4675	integrating	_	_	_	_
30-7	4676-4687	information	abstract[227]	giv[227]	coref	30-14[231_227]
30-8	4688-4690	on	abstract[227]	giv[227]	_	_
30-9	4691-4699	germline	abstract[227]|abstract|abstract[229]	giv[227]|giv|giv[229]	coref	30-16[232_229]
30-10	4700-4709	variation	abstract[227]|abstract[229]	giv[227]|giv[229]	_	_
30-11	4710-4714	from	_	_	_	_
30-12	4715-4719	GWAS	abstract	giv	_	_
30-13	4720-4724	with	_	_	_	_
30-14	4725-4736	information	abstract[231]	giv[231]	_	_
30-15	4737-4739	on	abstract[231]	giv[231]	_	_
30-16	4740-4747	somatic	abstract[231]|abstract[232]	giv[231]|giv[232]	_	_
30-17	4748-4751	and	abstract[231]|abstract[232]	giv[231]|giv[232]	_	_
30-18	4752-4762	epigenomic	abstract[231]|abstract[232]	giv[231]|giv[232]	_	_
30-19	4763-4772	variation	abstract[231]|abstract[232]	giv[231]|giv[232]	_	_
30-20	4773-4777	from	abstract[231]|abstract[232]	giv[231]|giv[232]	_	_
30-21	4778-4782	TCGA	abstract[231]|abstract[232]|abstract	giv[231]|giv[232]|giv	_	_
30-22	4783-4788	using	_	_	_	_
30-23	4789-4793	gene	abstract|abstract[235]	giv|giv[235]	_	_
30-24	4794-4804	expression	abstract[235]	giv[235]	_	_
30-25	4805-4807	as	_	_	_	_
30-26	4808-4811	the	abstract[237]	new[237]	_	_
30-27	4812-4825	intermediated	person|abstract[237]	new|new[237]	_	_
30-28	4826-4835	phenotype	abstract[237]	new[237]	_	_
30-29	4836-4837	.	_	_	_	_
